Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (40)COVID-19 (35)

Type

TypeGuidance (4959)Indicators (319)News (352)NICE advice (498)Quality standards (257)Research recommendations (1786)

Status

StatusAwaiting development (360)Discontinued (467)In consultation (11)In development (407)Published (2573)Topic prioritisation (385)

Last updated

Last updatedLast 3 months (203)Last 6 months (377)Last year (702)Last 3 years (1435)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (27)Antimicrobial resistance guidance (2)Cancer service guidelines (10)Clinical guidelines (392)COVID-19 rapid guidelines (27)Diagnostics guidance (89)Health technology evaluations (59)HealthTech guidance (778)Highly specialised technologies guidance (49)Interventional procedures guidance (1000)Medical technologies guidance (147)Medicines practice guidelines (5)NICE guidelines (579)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2313)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)NICE reviews (2)

Showing 2041 to 2055 of 8915 results

Sort by

Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Awaiting development Reference number: GID-TA11883 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
Awaiting development
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]
In development Reference number: GID-TA11674 Expected publication date: 07 May 2026
Result type
Technology appraisal guidance
Status
In development
Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
NPJ5008 for treating malignant hyperthermia [TSID11829]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation

Previous page
1
…
135
136
Current page 137
138
139
…
595
Page 137 of 595
Next page

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.